E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 2/7/2006 in the Prospect News Biotech Daily.

Jefferies keeps MannKind at hold

MannKind Corp. was maintained at a hold rating and a price target of $16 by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies believes the recent stock price appreciation (up 52% in 2006) fully reflects appropriate upside. The company reported fourth-quarter 2005 loss per share of $0.66, $0.37 below the analyst's estimate and 5 cents below Street consensus. Shares of the Valencia, Calif., biopharmaceutical company were down $1.01, or 5.89%, at $16.15 on volume of 400,413 shares versus the three-month running average of 282,821 shares. (Nasdaq: MNKD)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.